ReviewWorld journal of urology2021
Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions.
Review in World journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 64 citations in OpenAlex.
- A rare case of primary bladder malignant melanoma: a case report.Frontiers in oncology · 2026Article
- hsa-miR-145-3p defines a fibro-inflammatory bladder cancer subtype with distinct therapeutic vulnerabilities.Discover oncology · 2025Article
- ERO1A promotes the proliferation, migration and invasion of bladder cancer through ALOX5 mediated activation of JAK-STAT signaling pathway.Journal of translational medicine · 2025Article
- HLA-E and NKG2A Mediate Resistance to BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer.bioRxiv : the preprint server for biology · 2025Article
- CDCA4 promotes bladder cancer progression by JAK/STAT signaling pathway.Journal of cancer research and clinical oncology · 2025Article
- A Circadian Rhythm-related Signature to Predict Prognosis, Immune Infiltration, and Drug Response in Breast Cancer.Current medicinal chemistry · 2025Article
- Is miR-10a a tumor suppressor that modulates proliferation and invasion in high-grade bladder cancer?Oncology research · 2025Article
- Key immune cells and their crosstalk in the tumor microenvironment of bladder cancer: insights for innovative therapies.Exploration of targeted anti-tumor therapy · 2025Review
- Identifying functional cuproptosis-related long non-coding RNAs in patients with bladder cancer.Translational cancer research · 2024Article
- Basement membrane-related MMP14 predicts poor prognosis and response to immunotherapy in bladder cancer.BMC cancer · 2024Article
- Preliminary findings on the development of a predictive model for BLCA based on disulfidptosis-associated IncRNAs signature.BMC urology · 2024Article
- Promoting effect and immunologic role of secretogranin II on bladder cancer progression via regulating MAPK and NF-κB pathways.Apoptosis : an international journal on programmed cell death · 2024Article
- Article
- Revealing the mechanisms of RAC3 in tumor aggressiveness, the immunotherapy response, and drug resistance in bladder cancer.Frontiers in oncology · 2024Article
- Hydrogel-based formulations for urothelial cancer therapy.Frontiers in pharmacology · 2024Review
- Metabolomic Signatures of Treatment Response in Bladder Cancer.International journal of molecular sciences · 2023Review
- A novel immune checkpoint-related signature for prognosis and immune analysis in breast cancer.Clinical and experimental medicine · 2023Article
- Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer.Cancer immunology, immunotherapy : CII · 2023Review
- Apoptosis related genes mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide immunotherapy in bladder cancer.BMC medical genomics · 2023Article
- Recurrent primary malignant melanoma of the urinary bladder; a case report.Urology case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePatients harboring high-grade non-muscle-invasive bladder cancer (NMIBC) experience high rates of both recurrence and progression. Currently, few treatment options besides cystectomy exist for this at-risk population, especially those with BCG-unresponsive disease. The purpose of this review is to present the current status and describe future directions of immunotherapy in NMIBC.
methodsThe PubMed and Google Scholar databases were searched for articles pertaining to immunotherapy in NMIBC. Relevant planned and ongoing clinical trials were identified using www.ClinicalTrials.gov . Published randomized control trials, reviews, other retrospective and prospective studies deemed relevant were used in this review paper.
resultsNovel immunotherapies used in the treatment of high-grade NMIBC and BCG-unresponsive disease allow patients more options and have the potential to reduce the need for radical cystectomy. Currently, several options target the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) axis as this mechanism of immunotherapy has been shown to be effective in several cancers, including bladder, melanoma, and lung cancers. In addition, other immunotherapy options for the treatment of NMIBC include viral gene therapies, interleukin-15 superagonists, small molecule inhibitors of indoleamine (2,3)-dioxygenase 1, and vaccines.
conclusionsThe current landscape of immunotherapy in bladder cancer is rapidly evolving, with much literature pertaining to muscle-invasive and metastatic disease. However, the implementation of these treatment options in high-grade NMIBC may allow patients to avoid life-altering surgery. Reliable biomarkers for response are needed to further select patients who may benefit from such therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.